Lunit collabs with AstraZeneca, secures major deal in France 

Lunit and AstraZeneca have partnered to develop new AI-powered digital pathology solutions that predict non-small cell lung cancer (NSCLC). 

Based on a media release, their collaboration aims to accelerate the time-consuming process of genomic testing as part of NSCLC identification and diagnosis by leveraging Lunit's AI. The latter's solution can analyse H&E (hematoxylin and eosin) slide images to predict the likelihood of tumours with NSCLC driver mutations.  

Once they can validate their joint solution, they intend to deploy it in real-world settings, informing molecular testing for NSCLC further. Additionally, they will explore more molecular biomarkers to predict based on H&E slide analysis. 

_

Lunit has also recently announced that it was tapped by one of France's largest private radiology networks to deploy its mammography AI software. 

The Lunit INSIGHT MMG is expected to be implemented across over 400 sites of VIDI Group's network, which according to a press statement represents nearly a quarter of private radiology services in the country.

This network-wide deployment follows prior pilots involving some VIDI member radiology services that began in 2021. As part of this new partnership, Lunit will also be a recommended partner to the network members. 

In February last year, Lunit established a wholly-owned subsidiary in Europe based in the Netherlands. Since then, it has secured supply deals in Portugal and Sweden. In France, it supplies its lung disease detection AI to TeleDiag, another major radiology provider.  

Prediabetes risk feature live on Redcliffe app

Diagnostics service provider Redcliffe Labs in India has unveiled a pre-diabetes risk calculation feature on its Android mobile application. 

Powered by data analytics, the Prediabetes Risk Checker provides a snapshot of a user's diabetes risk by analysing their responses to lifestyle and genetic questions. The feature also generates personalised recommendations for lifestyle changes and further diagnostic testing.

Over 136 million people are living with prediabetes in India, Redcliffe notes.

Neurophet CTO now co-CEO

Neurophet has promoted its CTO to serve as co-CEO to Jake Junkil Been.

Donghyeon Kim, who is also co-founder of the medical AI company, was behind the development of Neurophet's foundational neuro-navigation system. As CTO, he also oversaw the company's neuroimaging analysis over the past eight years. Additionally, Kim currently serves as AI division manager at the Korea Medical Devices Industry Association Industry Development Committee.

His appointment as co-CEO comes as Neurophet doubles down on its global expansion, led by Been. Kim, on the other hand, will focus on ongoing R&D. 

This management change is also expected to drive Neurophet's planned listing on the KOSDAQ next year. The company was expected to do its IPO this year. 

Since last year, Neurophet has been pursuing partnerships and regulatory approvals in China and Singapore for its brain image analysis AI software offerings.